These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27436099)

  • 1. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.
    Wiebe S; Schnell D; Külzer R; Gansser D; Weber A; Wallenstein G; Halabi A; Conrad A; Wind S
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):461-469. PubMed ID: 27436099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
    Schnell D; Buschke S; Fuchs H; Gansser D; Goeldner RG; Uttenreuther-Fischer M; Stopfer P; Wind S; Petersen-Sylla M; Halabi A; Koenen R
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):267-75. PubMed ID: 24906422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.
    Wind S; Schmid M; Erhardt J; Goeldner RG; Stopfer P
    Clin Pharmacokinet; 2013 Dec; 52(12):1101-9. PubMed ID: 23813493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor.
    Mita S; Meyers D; Pal P; Lin T; Majumdar T; Rebello S; Sunkara G; Chen J
    Clin Pharmacokinet; 2015 Jul; 54(7):751-60. PubMed ID: 25627776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
    Stangier J; Rathgen K; Stähle H; Mazur D
    Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
    Allen A; Davis A; Hardes K; Tombs L; Kempsford R
    Clin Ther; 2012 Dec; 34(12):2316-32. PubMed ID: 23200625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment.
    Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1133-41. PubMed ID: 26526983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.
    Wind S; Schnell D; Ebner T; Freiwald M; Stopfer P
    Clin Pharmacokinet; 2017 Mar; 56(3):235-250. PubMed ID: 27470518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency.
    Lasseter KC; Sologuren A; La Noce A; Dilzer SC
    Clin Drug Investig; 2013 Sep; 33(9):665-73. PubMed ID: 23873362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.
    Cappuzzo F; Finocchiaro G; Grossi F; Bidoli P; Favaretto A; Marchetti A; Valente ML; Cseh A; Clementi L; Massey D; Santoro A
    J Thorac Oncol; 2015 Apr; 10(4):665-72. PubMed ID: 25514804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
    Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
    Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol.
    Bui K; She F; Sostek M
    J Clin Pharmacol; 2014 Dec; 54(12):1375-82. PubMed ID: 24946021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12.
    Liu Y; Zhou S; Assaf M; Nissel J; Palmisano M
    Clin Pharmacol Drug Dev; 2016 Nov; 5(6):469-479. PubMed ID: 27870479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.
    Ermer J; Corcoran M; Lasseter K; Marbury T; Yan B; Martin PT
    Ther Drug Monit; 2016 Aug; 38(4):546-55. PubMed ID: 26926668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics and safety of darapladib in subjects with severe renal impairment.
    Magee MH; Shaddinger B; Collins D; Siddiqi S; Soffer J
    Br J Clin Pharmacol; 2015 Oct; 80(4):654-61. PubMed ID: 25953363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
    Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
    Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.
    Stopfer P; Marzin K; Narjes H; Gansser D; Shahidi M; Uttereuther-Fischer M; Ebner T
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1051-61. PubMed ID: 22200729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
    Sidharta PN; Ulč I; Dingemanse J
    Clin Drug Investig; 2019 Nov; 39(11):1117-1123. PubMed ID: 31435905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment.
    Tayo B; Taylor L; Sahebkar F; Morrison G
    Clin Pharmacokinet; 2020 Jun; 59(6):747-755. PubMed ID: 31802404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
    Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
    Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.